Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.65 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.65 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.65 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.65 |
| ▸ | PDE5A | O76074 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.65 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.64 |
| ▸ | PRKCA | P17252 | 1/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.64 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | XBP1 | P17861 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19463533 | 0.94 | PTPN1 (0.62) | ESR1ABCG2ESR2AKR1B10AKR1B1 | |
| SCHEMBL19463534 | 0.94 | PTPN1 (0.62) | ESR1ABCG2ESR2AKR1B10AKR1B1 | |
| Phellamurin SCHEMBL27013577 | 0.85 | PTPN1 (0.47) | ESR1ABCG2ESR2AKR1B10AKR1B1 | |
| Phellamurin SCHEMBL30291874 | 0.85 | PTPN1 (0.47) | ESR1ABCG2ESR2AKR1B10AKR1B1 | |
| Munduleaflavanone B SCHEMBL14049994 | 0.83 | ESR1 (0.87) | ESR1ABCG2ESR2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL14304885 | 0.80 | ESR1 (1.00) | ESR1ABCG2ESR2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL1171435 | 0.80 | ESR1 (1.00) | ESR1ABCG2ESR2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL29396586 | 0.80 | ESR1 (1.00) | ESR1ABCG2ESR2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL147316 | 0.80 | ESR1 (1.00) | ESR1ABCG2ESR2AKR1B10AKR1B1 | |
| SCHEMBL4742873 | 0.80 | PTPN1 (0.46) | ESR1ABCG2ESR2PDE5APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635472-A1 | COSMETIC COMPOSITION COMPRISING AN EXTRACT OF FRAXINUS EXCELSIOR ASH BARK SOLUBILIZED IN JUGLANS REGIA WALNUT SEED OIL AND POLYGLYCERYL-4 OLEATE AND TOCOPHEROL | Société De Recherche Cosmétique S.à.r.L. (LU) | 2025-10-22 | — | — | EP | claimed |
| EP-4635472-A1 | COSMETIC COMPOSITION COMPRISING AN EXTRACT OF FRAXINUS EXCELSIOR ASH BARK SOLUBILIZED IN JUGLANS REGIA WALNUT SEED OIL AND POLYGLYCERYL-4 OLEATE AND TOCOPHEROL | Société De Recherche Cosmétique S.à.r.L. (LU) | 2025-10-22 | — | — | EP | disclosed |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | disclosed |
| CN-113876864-B | Pharmaceutical composition for treating infertility and preparation method and application thereof | 黑龙江中医药大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-113876864-A | Pharmaceutical composition for treating infertility and preparation method and application thereof | 黑龙江中医药大学 | 2022-01-04 | — | — | CN | disclosed |
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2021-07-29 | — | — | US | disclosed |
| US-10959979-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2021-03-30 | — | — | US | disclosed |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2020-08-27 | — | — | US | disclosed |
| US-10646465-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2020-05-12 | — | — | US | disclosed |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | ALONBIO LTD. (IL) | 2019-08-08 | — | — | US | disclosed |
| WO-2017103931-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10959979-B2 | Small molecules against cancer | CCL2, CXCR2, CCL5 | ESR1 3097/4885ABCG2 589/4885ESR2 1377/4885 |
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | ESR1 3097/4885ABCG2 589/4885ESR2 1377/4885 |
| US-10646465-B2 | Small molecules against cancer | CCL2, CXCR2, CCL5 | ESR1 3097/4885ABCG2 589/4885ESR2 1377/4885 |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | THPO, SERPINB1, SERPINC1 | ESR1 4309/4885ABCG2 1601/4885ESR2 3720/4885 |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | ESR1 3097/4885ABCG2 589/4885ESR2 1377/4885 |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | ESR1 3097/4885ABCG2 589/4885ESR2 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.